LIF and Huntington disease: Upon TI treatment, HD/ASCs and RD/ASCs upregulated their secretion of IL-6; there was also increased release of LIF from HD/ASCs and PGE2 from RD/ASCs while no changes were observed in the case of TGF-β, with the only exception of a smaller secretion of this cytokine by TI treated compared to untreated SSc/ASCs.